None
Conditions
Interventions
Group T:199mg bupivacaine liposome + 5 ml of NS in total 20ml for ACB
Group C:0.5% bupivacaine 20ml for ACB
Sponsors
The First Affiliated Hospital of Xinxiang Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 years old, with no gender limit; 2. ASA grades I-III; 3. Patients undergoing unilateral total knee replacement (TKA) under general anesthesia; 4.18 kg/m2<BMI<30kg/m2 5. Agreed to follow the study protocol and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. dication to local anesthetic or other study drugs, general anesthesia and / or adductor tube block 2. Medical history or evidence of increasing the risk of anesthesia during the screening period: ? Cardiovascular system: New York Heart Association (NYHA) grade III, IV heart failure, and (Adams-stokes) syndrome (ACS); requiring medication for bradycardia and / or heart rate 50 beats / min; history of severe arrhythmias including II-III degree atrioventricular block (excluding patients using pacemakers); acute and chronic myocarditis; patients requiring vasoactive drugs to maintain normal blood pressure; ? Patients with psychiatric disorders (such as schizophrenia, depression, etc.) and cognitive dysfunction; previous history of psychotropic drugs and narcotic drug abuse; previous history of alcohol abuse within 3 months before the screening period; ? Severe hepatic and renal insufficiency (liver function: refer to child-pugh C; renal function: glomerular filtration rate eGFR 30 mL / (min * 1.73 ?) [eGFR calculated using nephrology modified dietary test (MDRD) formula: eGFR=175 serum creatinine (Scr) -1.234 age-0.1790.79 (female)]; dialysis patients; ? Severe respiratory diseases, major seizure status, convulsions; craniocerebral injury, intracranial hypertension, cerebral aneurysm; 3. Pregnant and lactating women 4. Participate in the clinical trials of other drugs within 1 month before the screening 5. Other circumstances where the investigator determines that the patient is not fit to participate in the clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score (Resting and movement); | — |
Secondary
| Measure | Time frame |
|---|---|
| The condition of limb movement;Opioid dosage;Adverse drug reactions and sleep conditions; | — |
Countries
China
Contacts
Public ContactYongqiang Zhang
The First Affiliated Hospital of Xinxiang Medical College
Outcome results
None listed